美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

亚盛医药

40.40

-0.6400-1.56%

盘后：40.400.00000.00%16:10 EDT

成交量：3,944.00

成交额：16.02万

市值：37.64亿

市盈率：-54.92

高：40.98

开：40.98

低：40.34

收：41.04

52周最高：48.45

52周最低：16.50

股本：9,316.78万

流通股本：7,158.28万

量比：0.28

换手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-0.7356

每股收益(LYR):-0.7356

净资产收益率：-159.65%

总资产收益率：-22.77%

市净率：40.25

市盈率(LYR):-54.92

数据加载中...

总览公司新闻公告

全年营收大增342%背后，亚盛医药-B全球创新与商业化全面提速

全年营收大增342%背后，亚盛医药-B(06855)全球创新与商业化全面提速

智通财经网

异动解读 | 亚盛医药盘中大涨8.76%，2024年收入暴增342%远超预期

亚盛医药公布2024年业绩：迈入全球创新新阶段

异动解读 | 亚盛医药盘前大涨8.60%，年度收入暴增342%远超预期

亚盛医药2024年度收入9.81亿元同比增长342%

亚盛医药-B(06855)核心产品耐立克销售同比增长53%，双引擎驱动打开商业化空间

港股异动 | 亚盛医药-B(06855)现涨超9% 公司五项临床前研究进展入选2025年美国癌症研究协会年会

【AACR 2025】亚盛医药宣布将在2025年美国癌症研究协会年会上公布五项最新临床前进展

【亚盛医药-B(06855.HK)：五项临床前研究进展入选2025年美国癌症研究协会年会】亚盛医药-B(06855.HK)发布公告，公司共有五项临床前研究进展入选2025年美国癌症研究协会(AACR)年会。此次会议将于2025年4月25日至2025年4月30日在美国芝加哥举行。

亚盛医药-B(06855)：五项临床前研究进展入选2025年美国癌症研究协会年会

亚盛医药上涨2.35%，报19.14美元/股，总市值16.66亿美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/AAPG/news?page=9"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":40.4,"timestamp":1757448000000,"preClose":41.04,"halted":0,"volume":3944,"hourTrading":{"tag":"盘后","latestPrice":40.4,"preClose":40.4,"latestTime":"16:10 EDT","volume":34,"amount":1373.36,"timestamp":1757448603723},"delay":0,"floatShares":71582800,"shares":93167803,"eps":-0.735552,"marketStatus":"已收盘","change":-0.64,"latestTime":"09-09 16:00:00 EDT","open":40.98,"high":40.98,"low":40.3391,"amount":160198.261,"amplitude":0.015616,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1757491200000},"marketStatusCode":5,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":41.04,"postHourTrading":{"tag":"盘后","latestPrice":40.4,"preClose":40.4,"latestTime":"16:10 EDT","volume":34,"amount":1373.36,"timestamp":1757448603723},"volumeRatio":0.276959},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":0.276959,"shares":93167803,"dividePrice":0,"high":40.98,"amplitude":0.015616,"preClose":41.04,"low":40.3391,"week52Low":16.5,"pbRate":"40.25","psRate":"68.63","week52High":48.45,"institutionHeld":0,"latestPrice":40.4,"eps":-0.735552,"divideRate":0,"volume":3944,"delay":0,"ttmEps":-0.735552,"open":40.98,"prevYearClose":17.25,"prevWeekClose":40.4987,"prevMonthClose":42.47,"prevQuarterClose":39.375,"fiveDayClose":41.82,"twentyDayClose":40.04,"sixtyDayClose":32.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盘前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-09-08","current":-23.478386,"percent":0.980392,"low":-76.454813,"twenty":-59.602544,"median":-36.307775,"eighty":-31.810921,"high":-21.702816,"avg":-42.462654,"sd":14.204425,"marketCap":3817512539.24},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-08","current":-23.478386,"twenty":-59.602544,"median":-36.307775,"eighty":-31.810921,"marketCap":3817512539.24}],"updateTime":1757473315090},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522552870","title":"全年营收大增342%背后，亚盛医药-B全球创新与商业化全面提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2522552870","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522552870?lang=zh_cn&edition=fundamental","pubTime":"2025-03-28 07:55","pubTimestamp":1743119736,"startTime":"0","endTime":"0","summary":"2024年，港股医药板块受外部因素影响出现较大幅度下跌。从亚盛医药最新披露的2024年年报数据来看，报告期内，亚盛医药实现收入人民币9.81亿元，较去年同比大幅增长342%。其中，耐立克当期实现销售收入2.41亿元，同比增长约53%。此外，武田制药还投资7500万美元，溢价25%认购公司股份，成为亚盛医药重要的产业股东。武田积极合作的背后，侧面反映出耐立克巨大的全球商业化潜力。其中，中金公司维持对亚盛医药“跑赢行业”评级，并表示","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503280759489725c2f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503280759489725c2f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","AAPG"],"gpt_icon":0},{"id":"2522455787","title":"全年营收大增342%背后，亚盛医药-B(06855)全球创新与商业化全面提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455787","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455787?lang=zh_cn&edition=fundamental","pubTime":"2025-03-28 07:55","pubTimestamp":1743119700,"startTime":"0","endTime":"0","summary":"2024年，港股医药板块受外部因素影响出现较大幅度下跌。在此背景下，亚盛医药-B股价却在2024年全年股价累涨66.48%，大幅跑赢指数。从亚盛医药最新披露的2024年年报数据来看，报告期内，亚盛医药实现收入人民币9.81亿元，较去年同比大幅增长342%。其中，耐立克当期实现销售收入2.41亿元，同比增长约53%。截至2024年12月末，公司货币资金余额为12.61亿元，同比增长15.3%。其中，中金公司维持对亚盛医药“跑赢行业”评级，并表示，考虑","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-03-28/doc-inerehfs3207158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06855","AAPG"],"gpt_icon":0},{"id":"1171813650","title":"异动解读 | 亚盛医药盘中大涨8.76%，2024年收入暴增342%远超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1171813650","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171813650?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 21:52","pubTimestamp":1743083553,"startTime":"0","endTime":"0","summary":"亚盛医药今日盘中大涨8.76%，引起市场广泛关注。这一显著涨幅主要归因于公司刚刚发布的2024年度业绩报告，其中多项数据大幅超出市场预期。根据亚盛医药公布的2024年全年业绩报告，公司实现收入9.81亿元人民币，同比大幅增长342%。这意味着亚盛医药有望推出第二款重磅产品，进入\"双引擎\"驱动的新发展阶段。这些积极因素共同推动了投资者对亚盛医药未来发展前景的信心，从而带动股价上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"2522581414","title":"亚盛医药公布2024年业绩：迈入全球创新新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2522581414","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522581414?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 21:28","pubTimestamp":1743082080,"startTime":"0","endTime":"0","summary":"报告期内，亚盛医药实现收入人民币9.81亿元，较去年同比增长342%，增长主要来源于武田制药的选择权付款和耐立克（奥雷巴替尼）的强劲销售等 2024年耐立克实现销售收入达人民币2.41亿元，同比增长52% 2025年1月，亚盛医药完成在美国纳斯达克的首次公开发售，募资净额达人民币9.67亿元 报告期内，lisaftoclax（APG-2575）在中国的新药上市申请（NDA）获受理，并被纳入优先审评","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4651394_ZH51394_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK1161","BK1574","AAPG","06855"],"gpt_icon":0},{"id":"1167179150","title":"异动解读 | 亚盛医药盘前大涨8.60%，年度收入暴增342%远超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1167179150","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167179150?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 20:14","pubTimestamp":1743077693,"startTime":"0","endTime":"0","summary":"3月27日盘前，亚盛医药股价大涨8.60%，投资者对公司刚发布的2024年度业绩报告反应积极。根据公告，亚盛医药2024年全年实现收入9.81亿元人民币，同比大幅增长342%，远超市场预期。此外，亚盛医药在产品管线拓展方面也取得重要进展。这意味着亚盛医药有望推出第二款重磅产品，进入\"双引擎\"驱动的新发展阶段。同时，公司于2025年1月成功在美国纳斯达克上市，募集资金9.67亿元人民币，进一步增强了其财务实力和全球化发展潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"2522585374","title":"亚盛医药2024年度收入9.81亿元 同比增长342%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522585374","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522585374?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 19:30","pubTimestamp":1743075032,"startTime":"0","endTime":"0","summary":"3月27日，亚盛医药（06855）发布截至2024年12月31日止年度业绩公告。公司在报告期内实现收入9.81亿元，同比增长342%，主要受益于武田制药的选择权付款及耐立克?（奥雷巴替尼）强劲的销售。耐立克?在中国的销售收入达到2.41亿元，同比增长52%。此外，公司于2025年1月完成在美国纳斯达克的首次公开发售，募资净额1.33亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503273358175958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2522737621","title":"亚盛医药-B(06855)核心产品耐立克销售同比增长53%，双引擎驱动打开商业化空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2522737621","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522737621?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 19:14","pubTimestamp":1743074098,"startTime":"0","endTime":"0","summary":"报告期内，亚盛医药核心产品耐立克展现增长强劲态势，实现销售收入2.41亿元人民币，同比增长52%。亚盛医药2024全年实现收入9.81亿元人民币，较去年同比增长342%，增长主要来源于产品销售收入和对外合作授权收入等。值得一提的是，报告期内，亚盛医药就耐立克全球权益与武田达成BD，创下截止目前国内小分子肿瘤药领域的最大的对外权益许可的记录，为其将来的全球商业化进程奠定了基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1269154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4139","06855","AAPG","BK1161"],"gpt_icon":0},{"id":"2522391752","title":"港股异动 | 亚盛医药-B(06855)现涨超9% 公司五项临床前研究进展入选2025年美国癌症研究协会年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2522391752","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522391752?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 11:18","pubTimestamp":1743045483,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B现涨超9%，截至发稿，涨8.56%，报39.95港元，成交额1.54亿港元。消息面上，亚盛医药发布公告，公司共有五项临床前研究进展入选2025年美国癌症研究协会年会。值得注意的是，本月初亚盛医药公告，公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者。据悉，这是耐立克第三次获CDE纳入突破性治疗品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1268725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 亚盛医药-B(06855)现涨超9% 公司五项临床前研究进展入选2025年美国癌症研究协会年会","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","AAPG","BK1574","06855"],"gpt_icon":0},{"id":"2522891908","title":"【AACR 2025】亚盛医药宣布将在2025年美国癌症研究协会年会上公布五项最新临床前进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2522891908","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522891908?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 10:03","pubTimestamp":1742954580,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2025年3月26日 /美通社/ -- 致力于在血液肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司共有五项临床前研究进展入选2025年美国癌症研究协会年会。此次会议将于 2025 年 4 月 25 日至 30 日在美国芝加哥举行。截至目前，公司4个在研新药共获16项FDA和1项欧盟孤儿药资格认定，2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4650125_ZH50125_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","BK4139","06855","AAPG","BK1161"],"gpt_icon":0},{"id":"2522830029","title":"【亚盛医药-B(06855.HK)：五项临床前研究进展入选2025年美国癌症研究协会年会】亚盛医药-B(06855.HK)发布公告，公司共有五项临床前研究进展入选2025年美国癌症研究协会(AACR)年会。此次会议将于2025年4月25日至2025年4月30日在美国芝加哥举行。","url":"https://stock-news.laohu8.com/highlight/detail?id=2522830029","media":"金融界","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522830029?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 07:57","pubTimestamp":1742947052,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855.HK)发布公告，公司共有五项临床前研究进展入选2025年美国癌症研究协会(AACR)年会。此次会议将于2025年4月25日至2025年4月30日在美国芝加哥举行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/26075749045535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","BK1574","AAPG","BK1161","06855"],"gpt_icon":0},{"id":"2522304428","title":"亚盛医药-B(06855)：五项临床前研究进展入选2025年美国癌症研究协会年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304428","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304428?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 07:53","pubTimestamp":1742946802,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，公司共有五项临床前研究进展入选2025年美国癌症研究协会(AACR)年会。此次会议将于2025年4月25日至2025年4月30日在美国芝加哥举行。本次将要展示的数据涉及公司五个品种，包括：原创1类新药奥雷巴替尼(商品名：耐立克®;研发代号：HQP1351)、Bcl-2抑制剂APG-2575、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、胚胎外胚层发育蛋白(EED)抑制剂APG-5918以及IAP拮抗剂AS03157。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1267687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","BK1574","AAPG","06855"],"gpt_icon":0},{"id":"2519386532","title":"亚盛医药上涨2.35%，报19.14美元/股，总市值16.66亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2519386532","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519386532?lang=zh_cn&edition=fundamental","pubTime":"2025-03-14 03:05","pubTimestamp":1741892745,"startTime":"0","endTime":"0","summary":"3月14日，亚盛医药盘中上涨2.35%，截至03:05，报19.14美元/股，成交14.16万美元，总市值16.66亿美元。财务数据显示，截至2024年06月30日，亚盛医药收入总额8.24亿人民币，同比增长477.25%；归母净利润1.63亿人民币，同比增长140.51%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/14030548733326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","AAPG"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":9,"totalSize":172,"code":"91000000","status":"200"}]}}